rgn-137 LICENSE AgreementLicense Agreement • May 15th, 2014 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This License Agreement (this “Agreement” or this “License Agreement”) is effective as of March 7, 2014 (the “Effective Date”) by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaware, with offices at 15245 Shady Grove Road, Suite 470, Rockville, Maryland, U.S.A. (hereinafter “Licensor”), and Digital Aria Co., Ltd. with offices at 22nd FL, Parkview Tower, 248 Jungjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-863, Republic of Korea (hereinafter “Licensee”), each a “Party” and, collectively, the “Parties.”
SECURITIES PURCHASE AGREEMENT Dated as of March 7, 2014 Between REGENERX BIOPHARMACEUTICALS, INC. and DIGITAL ARIA CO., LTD.Securities Purchase Agreement • May 15th, 2014 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 7, 2014, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Digital Aria Co., Ltd. with offices at 22nd FL, Parkview Tower, 248 Jungjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-863, Republic of Korea (the “Investor”). (The Company and the Investor, individually, a “Party”, collectively, the “Parties”)
